MXPA02000969A - Vacuna de virus de inmuno-deficiencia humana atenuado controlado en forma condicional. - Google Patents

Vacuna de virus de inmuno-deficiencia humana atenuado controlado en forma condicional.

Info

Publication number
MXPA02000969A
MXPA02000969A MXPA02000969A MXPA02000969A MXPA02000969A MX PA02000969 A MXPA02000969 A MX PA02000969A MX PA02000969 A MXPA02000969 A MX PA02000969A MX PA02000969 A MXPA02000969 A MX PA02000969A MX PA02000969 A MXPA02000969 A MX PA02000969A
Authority
MX
Mexico
Prior art keywords
hiv
doxycycline
virus
doxsp
doxt
Prior art date
Application number
MXPA02000969A
Other languages
English (en)
Inventor
Smith Stephen
Original Assignee
Smith Stephen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Stephen filed Critical Smith Stephen
Publication of MXPA02000969A publication Critical patent/MXPA02000969A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion provee una vacuna de VIH atenuado que comprende un virus de VIH modificado para que se replique unicamente en presencia de por lo menos un analogo de tetraciclina. En forma adicional , la presente invencion provee un metodo para la inmunizacion de humanos contra VIH que comprende administrar a un humano una vacuna que incluya un virus de VIH modificado para que se replique unicamente en presencia de por lo menos un analogo de tetraciclina. En forma simultanea, se administra por lo menos un analogo de tetraciclina durante un periodo suficiente para permitir la replicacion del virus de VIH modificado in vivo en cantidad suficiente para producir inmunidad. De preferencia, el analogo de tetraciclina es doxiciclina. Se produce un genoma del virus VIH-DoxT de replicacion competente, el cual se puede controlar mediante la presencia o ausencia de doxiciclina preparando un promotor, TetopTCAT; produciendo un provirus, pVIH- DoxT, utilizando el promotor TetopCAT, y transfectando el pVIH-DoxT en lineas celulares en presencia de doxiciclina. Se produce un genoma del virus VIH-DoxSp de replicacion competente, el cual se puede controlar mediante la presencia o ausencia de doxiciclina preparando un promotor, TetopSpCAT; produciendo un provirus, pVIH-DoxSp, utilizando el promotor TetopCAT, y transfectando el pVIH-DoxSp en lineas celulares en presencia de doxiciclina. Las vacunas contra el VIH se preparan utilizando los genomas de los virus VIH-DoxT y VIH-DoxSp. Se administran estos virus y doxiciclina a hospederos humanos. La doxiciclina se administra durante un tiempo suficiente para acumular inmunidad y despues se detiene la administracion del farmaco de modo que los virus dependientes de doxiciclina ya no se replican.
MXPA02000969A 1999-07-28 2000-07-25 Vacuna de virus de inmuno-deficiencia humana atenuado controlado en forma condicional. MXPA02000969A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14608599P 1999-07-28 1999-07-28
PCT/US2000/040478 WO2001007637A2 (en) 1999-07-28 2000-07-25 Conditionally controlled, attenuated hiv vaccine

Publications (1)

Publication Number Publication Date
MXPA02000969A true MXPA02000969A (es) 2004-04-21

Family

ID=22515798

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02000969A MXPA02000969A (es) 1999-07-28 2000-07-25 Vacuna de virus de inmuno-deficiencia humana atenuado controlado en forma condicional.

Country Status (9)

Country Link
US (1) US6541003B1 (es)
EP (1) EP1203088B1 (es)
JP (1) JP2003526339A (es)
AT (1) ATE292186T1 (es)
AU (1) AU779076B2 (es)
CA (1) CA2380231C (es)
DE (1) DE60019125D1 (es)
MX (1) MXPA02000969A (es)
WO (1) WO2001007637A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083230A1 (en) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
US20080175836A1 (en) * 2005-12-09 2008-07-24 Karp Nelson M Immunogenic composition based on conditionally live virion and method for producing the same
AU2007345319B2 (en) 2006-07-13 2012-09-06 Institute For Advanced Study Viral inhibitory nucleotide sequences and vaccines
US20100129400A1 (en) * 2006-12-22 2010-05-27 The Penn State Research Foundation Attenuated viruses, vaccines and methods of use thereof
WO2008140622A2 (en) * 2006-12-22 2008-11-20 The Penn State Research Foundation Modified polymerases and attenuated viruses and methods of use thereof
JP2010525812A (ja) 2007-05-02 2010-07-29 メリアル リミテッド 発現及び安定性が改善されたｄｎａプラスミド
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
AU2011276223C1 (en) 2010-07-06 2016-05-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN116056722A (zh) 2020-04-20 2023-05-02 Nec奥克尔姆内特公司 Sars-cov-2疫苗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016060A1 (en) * 1993-01-11 1994-07-21 The Trustees Of The University Of Pennsylvania Mutants of hiv for supression of hiv infection
US5770414A (en) * 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
US5891718A (en) * 1996-03-27 1999-04-06 Vical Incorporated Tetracycline inducible/repressible systems

Also Published As

Publication number Publication date
WO2001007637B1 (en) 2001-11-22
AU779076B2 (en) 2005-01-06
JP2003526339A (ja) 2003-09-09
ATE292186T1 (de) 2005-04-15
CA2380231A1 (en) 2001-02-01
US6541003B1 (en) 2003-04-01
WO2001007637A2 (en) 2001-02-01
DE60019125D1 (de) 2005-05-04
WO2001007637A3 (en) 2001-08-23
EP1203088B1 (en) 2005-03-30
AU2482401A (en) 2001-02-13
EP1203088A2 (en) 2002-05-08
CA2380231C (en) 2009-01-06

Similar Documents

Publication Publication Date Title
MXPA02000969A (es) Vacuna de virus de inmuno-deficiencia humana atenuado controlado en forma condicional.
HUP0101139A2 (hu) Porított vakcinakészítmények transzdermális beadásra
ATE178490T1 (de) Cytopathische viren zur therapie und prophylaxe der neoplasie
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
NZ546298A (en) Immunogenic composition and method of developing a vaccine based on factor H binding sites
WO2004000209A3 (en) Administration of therapeutic viruses
JP2009514840A5 (es)
EP1030547A4 (en) METHODS FOR PREVENTING AND TREATING BACTERIAL INFECTIONS USING EXCIPIENTS BASED ON CELLULOSE ACETOPHTHALATE OR HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE
Decrausaz et al. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus‐associated genital tumors
US6878541B2 (en) Papilloma pseudo-virus and preparation
WO2002024897A3 (en) Conditionally replicating viral vectors and their use
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
ATE230276T1 (de) Verfahren zur erzeugung der toleranz eines säugetierpatientes gegen verabreichung von bei gentherapie gebrauchten viralen vektoren
AU6383296A (en) Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
OA09863A (en) Use of IL-4 to enhance immune response to immunogens in vaccines.
KR20120076396A (ko) 독성약화된 토끼 믹소마바이러스를 기본으로 한 모노파라뮤니티 유발인자
IL106491A0 (en) Anti viral preparations
JP2004529158A5 (es)
Ada Global aspects of vaccination
CA2350127A1 (en) Avipox vector coding an hiv antigen and a cytokine
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
IL139360A0 (en) Viral chimeras comprised of caev and hiv-1 genetic elements
Dentico et al. Immunogenicity and efficacy of anti-hepatitis B vaccines in hemodialysis patients
JPH07505613A (ja) 免疫不全ウイルスに対するワクチンとしての主要組織適合遺伝子複合体クラス２抗原
Polychrones World Vaccine Congress USA. Virtual-May 4-6, 2021